Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:AUPH NASDAQ:KOD NASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.16$4.22$2.93▼$7.55$521.94M1.462.25 million shs1.49 million shsAUPHAurinia Pharmaceuticals$16.97+1.1%$16.01$7.28▼$19.25$2.16B1.411.78 million shs2.03 million shsKODKodiak Sciences$38.96+3.2%$37.85$3.60▼$47.84$2.36B2.21841,429 shs1.55 million shsMLYSMineralys Therapeutics$26.98+0.4%$27.19$12.59▼$47.65$2.22B0.572.30 million shs2.03 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%-17.30%+3.10%+0.73%+25.68%AUPHAurinia Pharmaceuticals+1.07%-5.09%+10.70%+9.70%+100.35%KODKodiak Sciences+3.23%+5.16%+6.13%-8.99%+944.50%MLYSMineralys Therapeutics+0.37%+5.35%-14.35%+2.16%+99.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.16$4.22$2.93▼$7.55$521.94M1.462.25 million shs1.49 million shsAUPHAurinia Pharmaceuticals$16.97+1.1%$16.01$7.28▼$19.25$2.16B1.411.78 million shs2.03 million shsKODKodiak Sciences$38.96+3.2%$37.85$3.60▼$47.84$2.36B2.21841,429 shs1.55 million shsMLYSMineralys Therapeutics$26.98+0.4%$27.19$12.59▼$47.65$2.22B0.572.30 million shs2.03 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics0.00%-17.30%+3.10%+0.73%+25.68%AUPHAurinia Pharmaceuticals+1.07%-5.09%+10.70%+9.70%+100.35%KODKodiak Sciences+3.23%+5.16%+6.13%-8.99%+944.50%MLYSMineralys Therapeutics+0.37%+5.35%-14.35%+2.16%+99.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.50104.33% UpsideAUPHAurinia Pharmaceuticals 2.33Hold$17.251.65% UpsideKODKodiak Sciences 2.63Moderate Buy$42.148.17% UpsideMLYSMineralys Therapeutics 2.63Moderate Buy$49.3382.85% UpsideCurrent Analyst Ratings BreakdownLatest AQST, KOD, AUPH, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026MLYSMineralys Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/1/2026MLYSMineralys Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.005/1/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/27/2026MLYSMineralys Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/21/2026MLYSMineralys Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M11.72N/AN/A($0.28) per share-14.86AUPHAurinia Pharmaceuticals$283.05M7.71$1.02 per share16.57$4.41 per share3.85KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)AUPHAurinia Pharmaceuticals$287.20M$2.177.8221.21N/A99.97%26.62%19.65%7/30/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.05N/AN/AN/AN/A-27.92%-26.98%8/11/2026 (Estimated)Latest AQST, KOD, AUPH, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/7/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18$0.25+$0.07$0.25$76.98 million$77.71 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51-$0.47+$0.04-$0.47N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85AUPHAurinia Pharmaceuticals0.085.555.01KODKodiak SciencesN/A3.543.54MLYSMineralys TherapeuticsN/A44.3344.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%AUPHAurinia Pharmaceuticals36.83%KODKodiak Sciences89.06%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%AUPHAurinia Pharmaceuticals12.20%KODKodiak Sciences45.90%MLYSMineralys Therapeutics18.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.47 million116.91 millionOptionableAUPHAurinia Pharmaceuticals300128.60 million112.91 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableMLYSMineralys Therapeutics2882.50 million66.87 millionOptionableAQST, KOD, AUPH, and MLYS HeadlinesRecent News About These CompaniesMineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 24, 2026 | americanbankingnews.comWhat a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA DecisionJune 23, 2026 | fool.comDaphne Karydas Sells 3,000 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockJune 18, 2026 | insidertrades.comFindell Capital Management LLC Decreases Position in Mineralys Therapeutics, Inc. $MLYSJune 18, 2026 | marketbeat.comCatalio Capital Management LP Takes Position in Mineralys Therapeutics, Inc. $MLYSJune 18, 2026 | marketbeat.comMineralys Therapeutics, Inc. $MLYS Shares Purchased by Artia Global Partners LPJune 18, 2026 | marketbeat.comMineralys: Limited Differentiation Makes Lorundrostat A Weak CompetitorJune 17, 2026 | seekingalpha.comMineralys Therapeutics (MLYS) Prices $150M Public Offering of Common StockJune 17, 2026 | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Insider Sells $114,600.00 in StockJune 17, 2026 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 9,890 SharesJune 17, 2026 | marketbeat.comPolar Capital Holdings Plc Buys 342,365 Shares of Mineralys Therapeutics, Inc. $MLYSJune 17, 2026 | marketbeat.comMineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic AnalysisJune 14, 2026 | quiverquant.comQMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)June 14, 2026 | globenewswire.comInsider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 2,170 Shares of StockJune 12, 2026 | marketbeat.comDavid Malcom Rodman Sells 6,349 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockJune 12, 2026 | marketbeat.comMineralys Therapeutics (MLYS) to Repurchase Potential Royalties for LorundrostatJune 11, 2026 | insidermonkey.comMineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 11, 2026 | seekingalpha.comMineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 8, 2026 | globenewswire.comMineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)June 8, 2026 | globenewswire.comMineralys Deepens Lorundrostat Bet With Royalty Buyout And New DataJune 7, 2026 | finance.yahoo.comMineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical EfficacyJune 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAQST, KOD, AUPH, and MLYS Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.16 0.00 (0.00%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$4.26 +0.09 (+2.28%) As of 06/30/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Aurinia Pharmaceuticals NASDAQ:AUPH$16.97 +0.18 (+1.07%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$17.01 +0.04 (+0.24%) As of 06/30/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Kodiak Sciences NASDAQ:KOD$38.96 +1.22 (+3.23%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$38.90 -0.06 (-0.15%) As of 06/30/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Mineralys Therapeutics NASDAQ:MLYS$26.98 +0.10 (+0.37%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$26.63 -0.35 (-1.30%) As of 06/30/2026 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
